The proposed bill, known as the "Terminal Patients' Right to Try Act," aims to enhance access to potentially life-saving treatments for terminally ill patients in Rhode Island. It establishes a new chapter in Title 23 of the General Laws, which includes definitions for key terms such as "eligible patient," "innovative medical device," and "telehealth prescreening." The act expands upon federal law by streamlining access to investigational drugs, biologics, and devices, allowing for the use of innovative medical devices for diagnostic purposes, and facilitating telehealth prescreening and remote signing of consent forms.

The bill provides immunity to healthcare providers, manufacturers, and other entities involved in the care of patients using investigational therapies, provided certain conditions are met, including obtaining written informed consent. It specifies that eligible patients must be diagnosed with a terminal illness, have exhausted FDA-approved treatment options, and be unable to participate in clinical trials. The act also outlines the requirements for the use of innovative medical devices and the process for telehealth prescreening.

Additionally, the Director of the Department of Health is tasked with promulgating rules and regulations to implement and enforce the provisions of this chapter. This legislation is set to take effect on January 1, 2027.